ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$12.86+0.94%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ORIC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -37.1% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ORIC — earnings miss
Dated 2026-08-03
and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Why it matters: Updates on expenses show if the company can reduce losses. This is key for future funding.
Supportive ifOperating costs are down more than 5% from Q1 2026.
Worry ifOperating costs are up more than 5% from Q1 2026.
Why it matters: Cash burn trends show if the company can maintain its cash runway. This affects financial stability.
Worry ifOperating cash flow improves to less than -$30M in Q2 2026.
Less concerning ifOperating cash flow worsens to more than -$35M in Q2 2026.
Why it matters: Trends in R&D expenses will show how much ORIC is investing in its clinical programs. This affects long-term growth potential.
Watch forR&D expenses stabilize or decrease. This shows better cost management and efficiency.
Also watch forR&D expenses keep rising a lot. This suggests possible mismanagement of resources.
Why it matters: Earnings results will show if the company continues to beat expectations. This can impact investor confidence.
Supportive ifEarnings are more than 10% higher than what analysts expected.
Worry ifEarnings are more than 10% lower than what analysts expected.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$231 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $549 loss on $10,000 · 5.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,813 loss on $10,000 · 48.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash runway will show if ORIC can sustain operations. This affects investor confidence.
Worry ifCash and investments are over $380 million. This shows funding lasts into 2H 2028.
Less concerning ifCash and investments are below $380 million. This raises worries about staying in business.
Why it matters: Starting this trial is key for rinzimetostat's development in mCRPC. It could validate the drug's potential.
Supportive ifThe Himalayas-1 Phase 3 trial for rinzimetostat begins as planned in 1H 2026.
Worry ifThe trial initiation is delayed or canceled.
Why it matters: Enrollment progress in the Phase 3 trial will show demand for rinzimetostat. This is key for future growth.
Supportive ifEnrollment reaches or exceeds 600 patients as planned.
Worry ifEnrollment stalls or drops below 400 patients.
Why it matters: An update on rinzimetostat will show if the drug is progressing well in trials. This is key for ORIC's growth.
Supportive ifA good update on rinzimetostat's Phase 3 trial results or enrollment.
Worry ifNo update or a bad update on rinzimetostat's trial results.
Why it matters: Updates on enozertinib will indicate progress in its trials for NSCLC. This impacts ORIC's future value.
Supportive ifGood data from enozertinib trials shown at ESMO Congress 2026.
Worry ifThere is bad data or delays in updates about the enozertinib trial.